This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025
by Zacks Equity Research
PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.
RHHBYPositive Net Change BMYPositive Net Change NVONegative Net Change PRTANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates
by Zacks Equity Research
INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.
BEAMNegative Net Change INSMPositive Net Change ADPTPositive Net Change
biotechs earnings gene-therapy medical
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up
by Zacks Equity Research
NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.
REGNPositive Net Change BEAMNegative Net Change ANIPPositive Net Change NTLAPositive Net Change
biotechs earnings
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.
BAYRYPositive Net Change BEAMNegative Net Change PCRXNegative Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.
BAYRYPositive Net Change BEAMNegative Net Change ADMAPositive Net Change RCKTNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up
by Zacks Equity Research
Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.
SNYPositive Net Change NVAXPositive Net Change BEAMNegative Net Change ADPTPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Puma Biotechnology beats on first-quarter 2025 earnings and sales. Stock rises in after-hours trading
PBYIPositive Net Change ANIPPositive Net Change ADMAPositive Net Change IMCRNegative Net Change
biotechs
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut
by Zacks Equity Research
IOVA reports dismal first-quarter results. The share price plunges after the company significantly lowers its 2025 sales guidance.
BEAMNegative Net Change ADPTPositive Net Change IOVAPositive Net Change
biotechs cell-therapy medical
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?
by Ekta Bagri
ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025. We recommend the stock to prospective investors.
GRFSNo Net Change ADMAPositive Net Change TAKPositive Net Change
biotechnology biotechs earnings-report medical pharmaceuticals
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised
by Zacks Equity Research
MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance. Shares rise.
BEAMNegative Net Change ANIPPositive Net Change NTLAPositive Net Change MIRMNegative Net Change
biotechs earnings
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y
by Zacks Equity Research
AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.
BEAMNegative Net Change AMRNNegative Net Change ANIPPositive Net Change NTLAPositive Net Change
biotechs earnings
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
by Zacks Equity Research
CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
BAYRYPositive Net Change BEAMNegative Net Change CPRXPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
by Zacks Equity Research
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
BAYRYPositive Net Change BEAMNegative Net Change ADMAPositive Net Change APLSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
by Zacks Equity Research
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
BAYRYPositive Net Change BEAMNegative Net Change ADMAPositive Net Change ACADPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended
by Zacks Equity Research
CYTK reports narrower-than-expected Q1 loss. However, the target action date for aficamten in obstructive HCM has been extended by the FDA to provide time for reviewing a REMS submission made at the agency's request.
SNYPositive Net Change BAYRYPositive Net Change CYTKPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus
by Zacks Equity Research
DNLI reports a wider-than-expected loss for the first quarter of 2025. Denali submits a BLA for tividenofusp alfa under the FDA???s accelerated approval pathway based on data from the phase I/II study in participants with Hunter syndrome.
SNYPositive Net Change BIIBPositive Net Change DNLINegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View
by Zacks Equity Research
Halozyme reports better-than-expected first-quarter 2025 results. The company increases revenue guidance for 2025. Shares rise.
RHHBYPositive Net Change JNJNegative Net Change HALOPositive Net Change ANIPPositive Net Change
biotechs earnings
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
by Zacks Equity Research
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
JAZZPositive Net Change PBYIPositive Net Change NTLAPositive Net Change
biotechs cannabis earnings marijuana medical pharmaceuticals
Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
RARE reports weaker-than-expected first-quarter results, as earnings and revenues miss estimates despite a year-over-year increase in product sales.
REGNPositive Net Change BAYRYPositive Net Change RAREPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up
by Zacks Equity Research
NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy.
NVONegative Net Change LLYPositive Net Change BAYRYPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.
BEAMNegative Net Change ANIPPositive Net Change NTLAPositive Net Change IMCRNegative Net Change
biotechs earnings
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut
by Zacks Equity Research
SRPT reports mixed first-quarter 2025 results. The stock plunges after the company significantly lowers its 2025 sales guidance.
RHHBYPositive Net Change SRPTPositive Net Change ARWRPositive Net Change
biotechs earnings gene-editing gene-therapy medical pharmaceuticals
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks
by Zacks Equity Research
CRSP reports wider-than-expected first-quarter loss. Revenues also miss estimates. Stock tanks 12%.
VRTXPositive Net Change ADMAPositive Net Change CRSPPositive Net Change IMCRNegative Net Change
biotechs pharmaceuticals
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations
by Zacks Equity Research
Sales from VRTX's new drugs, Casgevy, Alyftrek and Journavx, in Q1 fell short of investor expectations.
VRTXPositive Net Change MRNAPositive Net Change CRSPPositive Net Change
biotechs
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down
by Zacks Equity Research
KRYS reports disappointing first-quarter 2025 results, with both earnings and sales missing estimates. Shares down.
BAYRYPositive Net Change BEAMNegative Net Change ADMAPositive Net Change KRYSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals